Log In
Print this Print this

Firazyr, icatibant

Also known as: JE049

  Manage Alerts
Collapse Summary General Information
Company Sanofi
DescriptionSelective peptidomimetic bradykinin B2 receptor antagonist
Molecular Target Bradykinin B2 receptor (BDKRB2) (B2R)
Mechanism of ActionBradykinin receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationAngioedema
Indication DetailsTreat acute attacks of angioedema; Treat acute attacks of hereditary angioedema (HAE); Treat angioedema; Treat angiotensin-converting-enzyme inhibitor (ACE-1) induced angioedema; Treat capillary leakage syndrome (CLS); Treat drug-induced angioedema; Treat hereditary angioedema (HAE)
Regulatory Designation U.S. - Orphan Drug (Treat acute attacks of hereditary angioedema (HAE));
EU - Orphan Drug (Treat acute attacks of hereditary angioedema (HAE));
Australia - Orphan Drug (Treat angiotensin-converting-enzyme inhibitor (ACE-1) induced angioedema)
Partner Shire plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today